专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9822587A3 Pituitary-tumor-transforming-genes, and related products 审中-公开
标题翻译：垂体肿瘤转化基因及相关产品
公开(公告)号：WO9822587A3
公开(公告)日：1998-08-06
申请号：PCT/US9721463
申请日：1997-11-21
申请人： CEDARS SINAI MEDICAL CENTER , MELMED SHLOMO , PEI LIN
发明人： MELMED SHLOMO , PEI LIN
IPC分类号： A01K67/027 , A61K31/7088 , A61K38/00 , A61K48/00 , A61P35/00 , C07K14/47 , C07K16/18 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/02 , C12P21/08 , C12Q1/68 , G01N33/53 , G01N33/574 , A01L67/027 , A61K38/17 , A61K39/395 , C12N15/11 , C12N15/85
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00 , A61K48/00 , Y10S435/81 , Y10S435/975
摘要： Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encoding them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in diagnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.

2. 发明申请

WO2009114817A3 PTTG1 AS A BIOMARKER FOR CANCER TREATMENT 审中-公开
公开(公告)号：WO2009114817A3
公开(公告)日：2009-09-17
申请号：PCT/US2009/037178
申请日：2009-03-13
申请人： CEDARS-SINAI MEDICAL CENTER , TONG, Yunguang , MELMED, Shlomo
发明人： TONG, Yunguang , MELMED, Shlomo
IPC分类号： C12Q1/68 , G01N33/574 , C12M1/34
摘要： The present invention relates to the use of pituitary tumor transforming gene 1 (PTTG1) as a biomarker for diagnosing cancer as well as for determining cancer treatment responsiveness. In one embodiment, the present invention provides a method of treating cancer by inhibiting the expression of PTTG1, and administering a therapeutically effective amount of Aurora kinase inhibitor, HDAC inhibitor and/or ROS-generating agent.

3. 发明申请

WO2012061601A1 TREATMENT OF PITUITARY CORTICOTROPH TUMORS USING R-ROSCOVITINE 审中-公开
标题翻译：使用R-ROSCOVITINE治疗原发性CORTICOTROPH肿瘤
公开(公告)号：WO2012061601A1
公开(公告)日：2012-05-10
申请号：PCT/US2011/059151
申请日：2011-11-03
申请人： CEDARS-SINAI MEDICAL CENTER , MELMED, Shlomo , LIU, Ning-Ai
发明人： MELMED, Shlomo , LIU, Ning-Ai
IPC分类号： A61K31/52 , A61P35/00
CPC分类号： A61K31/52 , A61K38/005 , A61K49/0008 , G01N33/5011 , G01N33/5088
摘要： The present invention describes methods of treating a pituitary tumor, methods of suppressing ACTH and/or corticosterone levels in an ACTH-secreting pituitary adenoma, methods of inhibiting the growth of an ACTH-secreting pituitary adenoma and methods of treating Cushing's disease. These methods can include providing a composition comprising R-roscovitin or a salt thereof and administering the composition to a mammalian subject in need thereof.
摘要翻译：本发明描述了治疗垂体肿瘤的方法，在分泌ACTH的垂体腺瘤中抑制ACTH和/或皮质酮水平的方法，抑制ACTH分泌性垂体腺瘤生长的方法和治疗库欣氏病的方法。这些方法可以包括提供包含R-roscovitin或其盐的组合物，并将该组合物施用于有需要的哺乳动物受试者。

4. 发明申请

WO2011094716A1 USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROLACTINOMA 审中-公开
标题翻译：使用酪氨酸激酶抑制剂治疗前列腺素
公开(公告)号：WO2011094716A1
公开(公告)日：2011-08-04
申请号：PCT/US2011/023237
申请日：2011-01-31
申请人： CEDARS-SINAI MEDICAL CENTER , FUKUOKA, Hidenori , COOPER, Odelia , MELMED, Shlomo
发明人： FUKUOKA, Hidenori , COOPER, Odelia , MELMED, Shlomo
IPC分类号： A61K39/395 , G01N33/48
CPC分类号： G01N33/573 , G01N33/5058
摘要： The invention relates to methods and kits for the treatment of, prevention of, and lowering the chances of developing prolactinomas by the administration of a tyrosine kinase inhibitor, such as lapatinib.
摘要翻译：本发明涉及通过施用酪氨酸激酶抑制剂如拉帕替尼来治疗，预防和降低发展为泌乳素瘤的机会的方法和试剂盒。

5. 发明申请

WO1998022587A2 PITUITARY-TUMOR-TRANSFORMING-GENES, AND RELATED PRODUCTS 审中-公开
标题翻译：临床肿瘤转化基因及相关产品
公开(公告)号：WO1998022587A2
公开(公告)日：1998-05-28
申请号：PCT/US1997021463
申请日：1997-11-21
申请人： CEDARS-SINAI MEDICAL CENTER , MELMED, Shlomo , PEI, Lin
发明人： CEDARS-SINAI MEDICAL CENTER
IPC分类号： C12N15/12
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00 , A61K48/00 , Y10S435/81 , Y10S435/975
摘要： Polypeptides are expressed by the pituitary-tumor-transforming-gene (PTTG), formerly known as pituitary-tumor-specific-gene (PTSG), and nucleic acids encoding them. Examples are the human and rat PTTG proteins. The nucleic acids may be applied to the production of a recombinant protein, and to the detection of the presence of PTTG genes in different species. The nucleic acids may be operatively linked to a vector, optionally provided with control and expression sequences and/or being carried by a host cell. The nucleic acids may also be delivered to a mammal to compensate for the absence, or a defective expression, of endogenous protein. The nucleic acids, proteins, and antibodies are also employed in diagnostic assays, as well as, for example, in the production of anti-PTTG antibodies (protein), therapeutic compositions and other applications of the proteins and antibodies. Various kits utilize nucleic acids, polypeptides, and/or antibodies. A transgenic non-human mammal expresses PTTG.
摘要翻译：多肽由垂体 - 肿瘤转化基因（PTTG）（以前称为垂体 - 肿瘤特异性基因（PTSG））和编码它们的核酸表达。实例是人和大鼠PTTG蛋白。核酸可以应用于重组蛋白的产生，以及检测不同物种中PTTG基因的存在。核酸可以可操作地连接到载体，任选地具有对照和表达序列和/或由宿主细胞携带。核酸也可以被递送到哺乳动物以补偿内源性蛋白质的缺失或缺陷表达。核酸，蛋白质和抗体也用于诊断测定，以及例如生产抗PTTG抗体（蛋白质），治疗组合物和蛋白质和抗体的其它应用。各种试剂盒利用核酸，多肽和/或抗体。转基因非人哺乳动物表达PTTG。

6. 发明申请

WO2011094722A1 USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF CUSHING'S DISEASE AND HYPERCORTISOLISM 审中-公开
标题翻译：酪氨酸激酶抑制剂用于治疗丘疹病和高血压的使用
公开(公告)号：WO2011094722A1
公开(公告)日：2011-08-04
申请号：PCT/US2011/023247
申请日：2011-01-31
申请人： CEDARS-SINAI MEDICAL CENTER , FUKUOKA, Hidenori , MELMED, Shlomo
发明人： FUKUOKA, Hidenori , MELMED, Shlomo
IPC分类号： C12N9/12 , A61K38/45 , A61K31/535
CPC分类号： A61K31/535 , C12Q1/485 , G01N33/74 , G01N2500/10 , G01N2800/048
摘要： The invention relates to methods and kits for the treatment of, prevention of, and lowering the chances of developing Cushing's Disease and/or hypercortisolism by the administration of a tyrosine kinase inhibitor, such as gefitinib.
摘要翻译：本发明涉及通过施用酪氨酸激酶抑制剂如吉非替尼来治疗，预防和降低发展库兴氏病和/或高皮质醇血症的机会的方法和试剂盒。

7. 发明申请

WO2009114817A2 PTTG1 AS A BIOMARKER FOR CANCER TREATMENT 审中-公开
标题翻译： PTTG1作为癌症治疗的生物标志物
公开(公告)号：WO2009114817A2
公开(公告)日：2009-09-17
申请号：PCT/US2009037178
申请日：2009-03-13
申请人： CEDARS SINAI MEDICAL CENTER , TONG YUNGUANG , MELMED SHLOMO
发明人： TONG YUNGUANG , MELMED SHLOMO
IPC分类号： A61K48/00
CPC分类号： G01N33/57423 , C12N15/113 , C12N15/1137 , C12N2310/14 , C12Y207/11001 , G01N33/57415 , G01N33/57419 , G01N2800/52 , Y10T436/143333
摘要： The present invention relates to the use of pituitary tumor transforming gene 1 (PTTG1) as a biomarker for diagnosing cancer as well as for determining cancer treatment responsiveness. In one embodiment, the present invention provides a method of treating cancer by inhibiting the expression of PTTG1, and administering a therapeutically effective amount of Aurora kinase inhibitor, HDAC inhibitor and/or ROS-generating agent.
摘要翻译：本发明涉及垂体瘤转化基因1（PTTG1）作为诊断癌症的生物标志物的用途以及用于确定癌症治疗反应性的用途。在一个实施方案中，本发明提供了通过抑制PTTG1的表达并施用治疗有效量的极光激酶抑制剂，HDAC抑制剂和/或ROS产生剂来治疗癌症的方法。

8. 发明申请

WO2006069188A1 METHOD FOR DRUG SCREENING AND CHARACTERIZATION BY ION FLUX ANALYSIS 审中-公开
标题翻译：通过离子通量分析进行药物筛选和表征的方法
公开(公告)号：WO2006069188A1
公开(公告)日：2006-06-29
申请号：PCT/US2005/046468
申请日：2005-12-21
申请人： CEDARS-SINAI MEDICAL CENTER , BEN-SHLOMO, Anat , MELMED, Shlomo , WAWROWSKY, Kolja
发明人： BEN-SHLOMO, Anat , MELMED, Shlomo , WAWROWSKY, Kolja
IPC分类号： G02B21/00 , G01N21/64 , G01N33/48
CPC分类号： G01N21/6458 , G01N21/6428 , G01N21/6486
摘要： The instrumentation and methods described herein are based on imaging and measuring single cell dose response by fluorescent ion imaging that records live cell responses to drug doses with no apparent damage to the cells or toxic side effects. Dose response curves and other pharmacological parameters can be computed by imaging and measuring oscillation changes for each dose and each cell. Large variability of cellular responses under the same experimental conditions indicates that pharmacological benchmarks are determined by statistical distribution of cells and cellular physiology. The instrumentation and methods described herein provide a means of measuring statistical variability of cell populations for improved screening and development methods for drugs.
摘要翻译：本文描述的仪器和方法基于通过荧光离子成像测量单细胞剂量反应的成像和测量，其记录对药物剂量的活细胞反应，对细胞没有明显的损伤或毒性副作用。可以通过成像和测量每个剂量和每个细胞的振荡变化来计算剂量反应曲线和其他药理学参数。在相同实验条件下细胞反应的大变异性表明药理学基准是通过细胞的统计分布和细胞生理学来确定的。本文所述的仪器和方法提供了测量细胞群体的统计变异性以改善药物的筛选和开发方法的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式